经尿道膀胱肿瘤切除术的质量控制指标:比利时多中心前瞻性嵌入式登记研究结果
本研究利用嵌入电子病历的电子病例报告表,前瞻性收集2013至2017年三家中心经尿道膀胱肿瘤切除术病例,回顾性收集病理数据,评估六项非肌层浸润性膀胱癌质量控制指标。共纳入907例患者的1151例手术,各指标依从性从31%到97%不等,中心间差异显著,丝裂霉素C单次灌注依从性与无复发生存显著相关。
要点
- 六项质控指标依从性:完全切除97%、逼尿肌存在31%、再次经尿道膀胱肿瘤切除术33%、丝裂霉素C单次灌注65%、卡介苗治疗39%、诊断后6周内治疗88%。
- 各中心间所有质控指标依从性差异显著,丝裂霉素C和再次经尿道膀胱肿瘤切除术依从性随时间显著提高。
- 丝裂霉素C依从性与无复发生存显著相关。
核心结论
- 基于电子病例报告表的经尿道膀胱肿瘤切除术登记可评估非肌层浸润性膀胱癌质控指标,并证明该方法在真实世界中的可行性。
- 中心间质控指标执行差异可激励泌尿外科医生改善日常诊疗,从而改善临床结局。
研究设计与样本
- 前瞻性多中心登记研究,使用嵌入电子病历的电子病例报告表前瞻性收集2013至2017年三家中心的经尿道膀胱肿瘤切除术临床数据,病理数据回顾性收集。
- 共收集1350例经尿道膀胱肿瘤切除术数据,最终纳入907例独特患者的1151例手术;排除T0疾病或既往T2疾病患者。
主要发现
- 经尿道膀胱肿瘤切除术后欧洲泌尿外科学会风险分类分布为低危271例、中危464例、高危416例。
- 两项质控指标的报告质量欠佳:逼尿肌为35%,卡介苗为51%。
- 质控指标依从性:完全切除97%、逼尿肌31%、丝裂霉素C单次灌注65%、再次经尿道膀胱肿瘤切除术33%、卡介苗39%、诊断后6周内治疗88%。
- 所有质控指标依从性在各中心间差异显著;丝裂霉素C和再次经尿道膀胱肿瘤切除术依从性随时间显著提高,可归因于一个中心。
- 丝裂霉素C依从性与无复发生存显著相关。
关键数值与推荐
- 完全切除状态依从性97%。
- 逼尿肌存在依从性31%,报告质量35%。
- 丝裂霉素C单次灌注依从性65%。
- 再次经尿道膀胱肿瘤切除术依从性33%。
- 卡介苗治疗依从性39%,报告质量51%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要研究局限是病理数据的回顾性收集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Quality control indicators (QCIs) can be used to objectively evaluate guideline adherence and benchmark quality among urologists and centers. OBJECTIVE: To assess six QCIs for non-muscle-invasive bladder cancer (NMIBC) using a prospective registry of transurethral resection of bladder tumor (TURBT) procedures. DESIGN, SETTING, AND PARTICIPANTS: Clinical data for TURBT cases were prospectively collected using electronic case report forms (eCRFs) embedded in the electronic medical record in three centers during 2013-2017. Pathological data were collected retrospectively. Patients with T0 disease or prior T2 disease were excluded. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We assessed six QCIs: complete resection (CR) status, presence of detrusor muscle (DM), re-TURBT, single instillation of mitomycin C (MMC), start of bacillus Calmette-Guérin (BCG) therapy, and therapy ≤6 wk after diagnosis. We assessed the quality of reporting on QCIs and compliance with QCIs, compared compliance between centers and over time, and investigated correlation between compliance and recurrence-free survival (RFS). RESULTS AND LIMITATIONS: Data for 1350 TURBT procedures were collected, of which 1151 were included for 907 unique patients. The distribution of European Association of Urology risk categories after TURBT was 271 with low risk, 464 with intermediate risk, and 416 with high risk. The quality of reporting for two QCIs was suboptimal, at 35% for DM and 51% for BCG. QCI compliance was 97% for CR, 31% for DM, 65% for MMC, 33% for re-TURBT, 39% for BCG, and 88% for therapy ≤6 wk after diagnosis. Compliance with all QCIs differed significantly among centers. Compliance with MMC and re-TURBT increased significantly over time, which could be attributed to one center. Compliance with MMC was significantly correlated with RFS. The main study limitation is the retrospective collection of pathology data. CONCLUSIONS: A TURBT registry consisting of eCRFs to collect pathology and outcome data allowed assessment of QCIs for NMIBC. Our study illustrates the feasibility of this approach in a real-life setting. Differences in performance on QCIs among centers can motivate urologists to improve their day-to-day care for patients with NMIBC, and can thus improve clinical outcomes. PATIENT SUMMARY: Our study demonstrates that quality control indicators for treatment of bladder cancer not invading the bladder muscle can be evaluated using electronic medical records. We assessed results for 1151 procedures in 907 individual patients to remove bladder tumors between 2013 and 2017 at three centers in Belgium. Compliance with the quality control indicators differed between centers, increased over time, and was correlated with recurrence of disease.
引用
- Muilwijk T, Akand M, Raskin Y, et al. Quality Control Indicators for Transurethral Resection of Bladder Tumor: Results from an Embedded Belgian Multicenter Prospective Registry. Eur Urol Oncol. 2022. PMID: 36543720. doi:10.1016/j.euo.2022.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。